Novel targets and uses for the diagnosis and treatment of dementia

TNF derivative polypeptides serve as diagnostic markers and therapeutic agents for dementia, offering objective and cost-effective solutions for diagnosing and treating Alzheimer's and vascular dementia, addressing the limitations of current methods.

JP2024543703AInactive Publication Date: 2024-11-21SHANGHAI JW INFLINHIX CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024536247
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-15
Filing Date
2022-12-15
Publication Date
2024-11-21
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods for diagnosing and treating dementia, particularly Alzheimer's disease and vascular dementia, are limited and lack effective biological targets, leading to ineffective diagnostic and therapeutic strategies.

Method used

Utilization of TNF derivative polypeptides as markers, reagents, or drugs for diagnosing and treating dementia, including specific polypeptides with sequences similar to SEQ ID NOs: 2-26, and their corresponding antibodies or antagonists, which are used in kits and compositions for detection and treatment.

Benefits of technology

The TNF derivative polypeptides provide objective, accurate, and cost-effective diagnostic tools and therapeutic options for dementia, reducing patient discomfort and costs compared to existing methods, with potential for early intervention and treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543703000001_ABST
    Figure 2024543703000001_ABST
Patent Text Reader

Abstract

The present invention relates to targets for the diagnosis and treatment of dementia. The present invention also relates to methods for diagnosing and treating dementia with these targets. The diagnosis of dementia by the method of the present invention has the advantages of easy material acquisition, low cost, rapid detection, and objective and accurate detection results.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of medicine. In particular, the present invention relates to new targets for the diagnosis and treatment of dementia, and the use of these targets for the diagnosis and treatment of dementia. [Background technology]

[0002] Dementia is a neurodegenerative disease whose main clinical manifestation is the decline of advanced cognitive function, and is characterized by progressive intellectual decline, cognitive impairment, and personality changes. As the aging of the social population progresses, the incidence of dementia increases year by year, placing a heavy economic and mental burden on patients and their families, and dementia has already become a public and social problem that needs to be solved all over the world. There are many types of dementia, among which Alzheimer's disease (AD) and vascular dementia (VD) are the two most common types of dementia, accounting for more than 90% of all dementia patients. AD is a progressive neurodegenerative disease, and its clinical manifestations are cognitive impairment and memory loss. Pathological characteristics include diffuse cerebral cortical atrophy, amyloid plaques due to abnormal accumulation of extraneuronal amyloid beta (Aβ), and neurofibrillary tangles (NFTs) due to aggregation of Tau protein in neurons. As the aging of the population becomes more serious, it is expected that by 2050, 100 million people worldwide will suffer from AD. VD is the second most common form of dementia after AD, accounting for approximately 15% of dementia cases. Acute focal ischemia due to cerebral reperfusion, long-term chronic reduced blood flow perfusion, long-term hypertension, hyperglycemia, senility, and cerebral sedimentation can all induce damage to the blood-brain barrier, causing structural changes in cerebral blood vessels, ultimately leading to VD. Blood-brain barrier damage plays an important role in the pathological mechanism of VD.

[0003] The current main detection methods for dementia are limited to neuroimaging tests and neuropsychological tests (in the form of psychological scales). As its etiology and mechanism are still unclear, there is currently no specific medicine to treat dementia, and no specific biochemical and immunological diagnostic methods. Scholars believe that it is mainly related to the death of nerve cells due to many factors such as genes and environment. Most of the research is focused on the research and development of diagnostic and therapeutic approaches that mainly target Aβ and Tau. At present, many clinical trials have failed. Recently, one treatment for Aβ was approved by the US FDA, but it has been reported that the review process was apparently controversial.

[0004] In other words, current research has yet to provide effective diagnostic and therapeutic methods. The holy grail in this field is the discovery of biological targets more relevant to the triggers of dementia and the research and development of diagnostic and therapeutic plans surrounding those biological targets. Summary of the Invention

[0005] An object of the present invention is to provide a new target for diagnosing and treating dementia. In a first aspect, the present invention provides a TNF derivative polypeptide for use (1) as a marker for diagnosing or detecting dementia, (2) for the manufacture of a reagent or kit for diagnosing or detecting dementia, or (3) for the manufacture of a medicament for treating dementia.

[0006] In specific embodiments, the TNF derivative polypeptide is one or more selected from the following: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26. In specific embodiments, said dementia is Alzheimer's disease or vascular dementia.

[0007] In a second aspect, the present invention provides a kit for diagnosing or detecting dementia, comprising a detection reagent and a container for containing the detection reagent, The detection reagent detects the presence or absence of a TNF derivative polypeptide or an antibody capable of binding to the TNF derivative polypeptide in the serum of a test subject, and the TNF derivative polypeptide is:

[0008] 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26. In a preferred embodiment, the kit further instructs an operator how to The present invention includes instructions for use in diagnosing or detecting dementia using the detection reagent.

[0009] In a third aspect, the present invention provides a TNF derivative polypeptide which is: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 4-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 4-26.

[0010] In preferred embodiments, the TNF derivative polypeptide is used (1) as a marker for diagnosing or detecting dementia, (2) for the manufacture of a reagent or kit for diagnosing or detecting dementia, or (3) for the manufacture of a drug for treating dementia. In a preferred embodiment, the dementia is Alzheimer's disease or vascular dementia.

[0011] In a fourth aspect, the present invention provides a combination of two or more TNF derivative polypeptides selected from the group consisting of: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26.

[0012] In a preferred embodiment, the TNF derivative polypeptide combination is used (1) as a marker for diagnosing or detecting dementia, (2) for the manufacture of a reagent or kit for diagnosing or detecting dementia, or (3) for the manufacture of a drug for treating dementia. In a preferred embodiment, the dementia is Alzheimer's disease or vascular dementia.

[0013] In a fifth aspect, the present invention provides a binding agent or antagonist of a TNF derivative polypeptide, wherein the TNF derivative polypeptide is: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26.

[0014] In a preferred embodiment, the binding agent or antagonist includes, but is not limited to, an antibody, a small molecule compound having a binding or antagonistic activity to the TNF derivative polypeptide, or a protein or polypeptide having a binding or antagonistic activity to the TNF derivative polypeptide. In a preferred embodiment, the dementia is Alzheimer's disease or vascular dementia.

[0015] In a sixth aspect, the present invention provides the use of a binder or antagonist of a TNF derivative polypeptide for the manufacture of a medicament for treating dementia, wherein the TNF derivative polypeptide is: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26.

[0016] In a preferred embodiment, the binding agent or antagonist includes, but is not limited to, an antibody, a small molecule compound having a binding or antagonistic activity to the TNF derivative polypeptide, or a protein or polypeptide having a binding or antagonistic activity to the TNF derivative polypeptide. In a preferred embodiment, the dementia is Alzheimer's disease or vascular dementia.

[0017] In a seventh aspect, the present invention provides a pharmaceutical composition comprising a TNF derivative polypeptide binding agent or antagonist and optionally a pharma- ceutically acceptable excipient, wherein the TNF derivative polypeptide is: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26.

[0018] In a preferred embodiment, the binding agent or antagonist includes, but is not limited to, an antibody, a small molecule compound having a binding or antagonistic activity to the TNF derivative polypeptide, or a protein or polypeptide having a binding or antagonistic activity to the TNF derivative polypeptide. In a preferred embodiment, the dementia is Alzheimer's disease or vascular dementia.

[0019] In an eighth aspect, the present invention provides a method for detecting or diagnosing dementia, the method comprising the steps of: 1) detecting the presence or absence of a TNF derivative polypeptide or an antibody capable of binding to said TNF derivative polypeptide in the serum of a subject, said TNF derivative polypeptide being a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs:2-26, or a polypeptide having 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence similarity to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs:2-26; 2) If the TNF derivative polypeptide or an antibody capable of binding to the derivative polypeptide is present in the serum of the subject, the subject is judged to have dementia. In a preferred embodiment, the dementia is Alzheimer's disease or vascular dementia.

[0020] In a ninth aspect, the present invention provides a method for prognosing dementia, the method comprising the steps of: 1) detecting the presence or absence of a TNF derivative polypeptide or an antibody capable of binding to said TNF derivative polypeptide in the serum of a subject, said TNF derivative polypeptide being a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs:2-26, or a polypeptide having 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence similarity to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs:2-26;

[0021] 2) If the TNF derivative polypeptide or an antibody capable of binding to the derivative polypeptide is present in the serum of the subject, the prognosis of the dementia of the subject is judged to be poor. In a preferred embodiment, the dementia is Alzheimer's disease or vascular dementia.

[0022] Of course, it is understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (for example, in the Examples) can be combined with each other to form new or preferred technical solutions, which will not be described here one by one due to space limitations. [Brief description of the drawings]

[0023] [Figure 1] FIG. 1 shows a comparison of TNFα antibodies and TNF-Ab in the sera of Alzheimer's disease patients, vascular dementia patients, age-matched controls, and healthy subjects. [Diagram 2] FIG. 2 shows a comparison of P1516-Ab in the serum of Alzheimer's disease patients and age-matched controls. [Diagram 3] FIG. 3 shows a comparison of P1516-Ab in the sera of Alzheimer's disease patients and 100 healthy subjects. [Figure 4] FIG. 4 shows a comparison of serum P1516-Ab concentrations between patients with vascular dementia and age-matched controls. [Diagram 5] FIG. 5 shows a comparison of P1516-Ab concentrations in the serum of patients with vascular dementia and 100 healthy subjects. [Figure 6] FIG. 6 shows a comparison of P141516-Ab concentrations in serum of VD patients and age-matched controls. [Figure 7] FIG. 7 shows a comparison of P141516T-Ab concentrations in serum of VD patients and age-matched controls. [Figure 8] FIG. 8 shows a comparison of P1213-Ab concentrations in the bodies of patients and age-matched controls. [Figure 9] FIG. 9 shows a comparison of P1213-Ab concentrations in the bodies of patients and 100 healthy subjects. [Figure 10] FIG. 10 shows a comparison of P1920-Ab concentrations in the bodies of patients and age-matched controls. [Figure 11]FIG. 11 shows a comparison of P1920-Ab concentrations in the bodies of patients and 100 healthy subjects. [Figure 12] FIG. 12 shows the main sequences targeted by the P1516 antibody in patients and the control results of serum from healthy individuals. [Figure 13] The sequence in Figure 13 is the TNF-α sequence, and the different colored fragments represent fragments with different amino acid numbers in the serum of dementia patients detected in the mass spectrometry test. The positions where P1213, P1516, and P1920 are present are indicated by blue arrows. Many of the fragments detected in the serum of patients are concentrated in that region. [Figure 14] In Figure 14, HMC3 cells (1x104 cells / well) were co-cultured with LPS (1ug / ml), IL-4 (20ng / ml), TNF (20ng / ml), and a series of TNF derivative polypeptides (50uM / ml, P78-P2122) for 24h, and three duplicate wells were prepared for each group. Then, cck8 reagent was added and co-cultured with the cells for another 1h, and the absorbance at OD450nm was detected. C1: Cells only, C2: LPS, C3: IL-4. [Figure 15] FIG. 15 compares the detection of relevant antibodies in the sera of Alzheimer's disease (AD), vascular dementia (VD), age-matched controls (Control), and healthy controls (Health) using the polypeptides of the present invention alone or in combination. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] Through extensive and in-depth research, the present inventors have unexpectedly found a series of TNF derivative polypeptides, which have a very clear association with dementia and are therefore useful for diagnosing and treating dementia. Based on this, the present invention has been completed.

[0025] TNF and TNF-Derivative Polypeptides Tumor necrosis factor (TNF) is a multifunctional cytokine that not only promotes cell proliferation and induces inflammatory responses, but also kills tumor cells. It is secreted by many cells, mainly macrophages and T cells, among which TNF-α, the so-called TNF, is secreted by monocyte-macrophages, and lymphotoxin, also called TNF-β, is secreted by activated T cells. TNF is the first cytokine whose levels increase in inflammatory responses, and was named after its ability to induce rapid hemorrhagic necrosis of experimental cancers. It has profound and diverse physiological and pathological effects on the body, and is closely related to many acute and chronic inflammatory diseases.

[0026] Tumor necrosis factor-α (TNF-α) is associated with many inflammatory diseases. However, studies of TNF in dementia have been inconsistent. One study found that the rate of dementia in patients with tumor necrosis factor-associated inflammatory diseases was improved compared to controls, but neutralizing antibodies that block the action of TNF had little effect in treating dementia. Detection of TNF in peripheral blood did not show a significant association with dementia.

[0027] In the course of research, the inventor unexpectedly found that while the TNF level in peripheral blood has no significant correlation with dementia, the levels of TNF antibodies and the TNF derivative polypeptides P1516, P1213, P1920 and a series of polypeptides consisting of 10-20 amino acids derived from P1516 have a very clear correlation with dementia (Figures 1-12). In the serum of dementia patients, antibodies against the corresponding TNF or TNF derivative polypeptides are detected at significantly higher levels than those of healthy subjects or patients with other diseases.

[0028] Furthermore, the inventors demonstrated through mass spectrometry testing that the serum of dementia patients with high levels of derivative polypeptide antibodies indeed contained polypeptide fragments of similar size and high sequence similarity, such as P1213, P1516, and P1920 (Figure 13).

[0029] Thus, the TNF derivative polypeptide of the present invention may be a polypeptide having an amino acid sequence as set forth in any of SEQ ID NOs:2-26, or the TNF derivative polypeptide of the present invention may be a polypeptide having sequence similarity of at least 80%, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence as set forth in any of SEQ ID NOs:2-26.

[0030] The present inventors further found that when comparing the detection of relevant autoantibodies in the serum of Alzheimer's disease (AD), vascular dementia (VD), age-matched controls (Control), and healthy controls (Health) using the polypeptides of the present invention alone or in combination, the use of the combination provides higher sensitivity in detecting the relevant antibodies themselves (Figure 15). Therefore, the TNF derivative polypeptide of the present invention may be a combination of two or more of the above polypeptides.

[0031] Uses of the TNF derivative polypeptides of the present invention Through in vitro cell experiments, the inventors have demonstrated that the derivative polypeptides can effectively kill microglia HMC3 cells in human neural tissue (Figure 14). Therefore, these polypeptides are useful as biological targets for the diagnosis and treatment of dementia. Detection of antibodies against these polypeptides and regulation of these biological targets are useful for early intervention in dementia patients and for the prevention and treatment of the onset and development of dementia. A series of polypeptides of the present invention are useful for the clinical diagnosis of AD and VD, and it is possible to develop corresponding treatment plans around these polypeptides.

[0032] Based on the above discoveries, the present invention provides the use of the TNF derivative polypeptide (1) as a marker for diagnosing or detecting dementia, (2) for the manufacture of a reagent or kit for diagnosing or detecting dementia, or (3) for the manufacture of a drug for treating dementia. kit

[0033] The present invention also provides a kit for diagnosing or detecting dementia, comprising a detection reagent and a container for containing said detection reagent, said detection reagent detecting the presence or absence of a TNF-derivative polypeptide or an antibody capable of binding to said TNF-derivative polypeptide in the serum of a subject. The kit may further comprise instructions for use instructing an operator how to use the detection reagent to diagnose or detect dementia.

[0034] Based on the above TNF derivative polypeptide or kit, the present invention further provides a method for detecting, diagnosing or prognosing dementia, comprising detecting the presence or absence of a TNF derivative polypeptide or an antibody capable of binding to said TNF derivative polypeptide in the serum of a subject, and judging that the dementia of the subject has a poor prognosis if said TNF derivative polypeptide or an antibody capable of binding to said derivative polypeptide is present in the serum of the subject.

[0035] Antagonists of the TNF derivative polypeptides of the present invention The term "antagonist" as used herein has the meaning commonly understood by those of skill in the art: a substance that, when bound to a receptor or receptor system, does not itself elicit a biological effect, but blocks the action mediated by the receptor agonist.

[0036] The present inventors have demonstrated that said derivative polypeptide can effectively kill the microglial cells HMC3 of human neural tissue, so that said TNF derivative polypeptide antagonist can be used to produce a drug for treating dementia.

[0037] In specific embodiments, antagonists of the TNF-derivative polypeptides of the present invention include, but are not limited to, antibodies, small molecule compounds having an antagonistic effect on the TNF-derivative polypeptides of the present invention, proteins or polypeptides having an antagonistic effect on the TNF-derivative polypeptides of the present invention. In a preferred embodiment, the TNF-derivative polypeptides of the present invention may be inhibitors of said TNF-derivative polypeptides.

[0038] Based on the antagonist of TNF derivative polypeptide, the present invention further provides a pharmaceutical composition comprising said antagonist, which can be used for the treatment of dementia, such as Alzheimer's disease or vascular dementia.

[0039] The main advantages of the present invention are: 1. The material is easy to obtain, and the polypeptide of the present invention is useful for diagnosing dementia. It can be detected by collecting a small amount of peripheral blood from the patient, without the need to collect cerebrospinal fluid, thereby reducing the pain of the patient. 2. Low cost: It is cheaper than head PET, CT and MRI scans. 3. Detection is rapid, with experimental results available in only 2 hours. 4. Compared with relatively subjective detection methods such as psychological scales, the detection method of the present invention uses machine-read results, which is more objective and accurate.

[0040] The technical solution of the present invention will be further described below with specific examples, but the following examples do not limit the present invention, and various application methods used according to the principles and technical means of the present invention are all included in the scope of the present invention. In the following examples, the experimental methods without specific conditions were usually carried out under normal conditions or conditions recommended by the manufacturer. Unless otherwise specified, % and parts are calculated by weight.

[0041] Example 1. Synthesis of Polypeptides P1516, P1213, and P1920 are polypeptides with a total length of 30 amino acids, and their synthesis was commissioned to Ontores Biotechnologies Co., Ltd., Hangzhou, China.

[0042] Based on the full length of P1516, we designed polypeptides with sizes of 10 and 20 amino acids, respectively, and commissioned Allpeptide Co., Ltd., Hangzhou, China, to synthesize them. Among them, the polypeptides 10-1 to 10-21 are 10 amino acids long, and each polypeptide, except for 10-1, overlaps with the previous polypeptide by 9 amino acids. The polypeptides 20-1 to 20-11 are 20 amino acids long, and each polypeptide, except for 20-1, overlaps with the previous polypeptide by 19 amino acids.

[0043] P141516 is a polypeptide of 40 amino acids in length. P141516-Trun is a polypeptide synthesized by knocking out the five amino acid residues at the head end and the four amino acid residues at the tail end of P141516. The sequences of all the synthesized polypeptides are shown in the table below. [Table 1]

[0044] Example 2. Patient serum detection 1. Selection and exclusion criteria for patient serum samples AD Selection Criteria: 1.Meets diagnostic criteria for an organic mental disorder; 2. Total intellectual disability; 3. Absence of sudden stroke-like episodes and no evidence of focal neurological damage early in the disease; 4. There is no clinical or special test evidence that the intellectual disability is due to disease of other parts of the body or the brain; 5. The following features support the diagnosis but are not required: 5.1 Higher cortical functions are impaired, with aphasia, agnosia, and apraxia; 5.2 Coldness, lack of initiative, or irritability and uncontrollable social behavior; 5.3 In severe, terminal cases, there are parkinsonian symptoms and epileptic seizures; 5.4 In the nervous system, laboratory tests show evidence of brain atrophy; 6. Neuropathological examination is helpful in confirming the diagnosis.

[0045] Exclusion criteria for AD: Rule out intellectual disability due to other organic brain lesions such as cerebrovascular disease, pseudodementia due to psychiatric disorders such as depression, mental retardation, or benign amnesia in the elderly.

[0046] VD selection criteria: 1. Male or female outpatients or inpatients aged 50-85 years; 2. Primary school or higher education; 3. Head MRI showed vasculogenic white matter hyperintensity (Fazekas score ≥ 1 point) and ≥ 1 lacunar lesion; 4.Meet at least one of the following clinical findings:

[0047] (1) A history of lacunar stroke syndrome in clinical practice (clinical findings of acute lacunar infarction syndrome and symptoms on head MRI, with an associated de novo lesion ≤20 mm located in the subcortical white matter or basal ganglia region); (2) Asymptomatic or cognitively impaired (abnormalities in memory and / or other cognitive domains persisting for at least 3 months), cognitive impairment may be causally related to cerebrovascular disease, and cognitive decline is characterized by sudden or wavelike, gradual progression of cognitive decline, impaired executive function, impaired concentration, mild cognitive impairment of the subcortical type, or subcortical vascular dementia; (3) Emotional disorders: depression or anxiety; (4) Bladder dysfunction: urinary incontinence, etc.; (5) Gait abnormalities: Parkinsonian gait, etc. (6) Pseudobulbar palsy: dysphagia, dysarthria, forced crying and laughing, etc.; 5. Sign the consent form.

[0048] Exclusion criteria for VD: 1. Patients with new TOAST-classified nonlacunar cerebral infarction or intracerebral hemorrhage within 6 months; 2. Concomitant hydrocephalus and other non-vascular cerebral white matter lesions (e.g., multiple sclerosis, carbon monoxide toxic encephalopathy, etc.); 3. Systemic diseases leading to cognitive impairment (e.g. liver or kidney dysfunction, endocrine disorders, vitamin deficiencies, systemic autoimmune diseases, etc.); 4. Associated depression (Hamilton Depression Rating Scale score ≥ 17 points) or other unassociated severe psychiatric illness (schizophrenia, bipolar disorder, or delirium);

[0049] 5. Severe nervous system diseases: for example, central nervous system infections, Creutzfeldt-Jakob disease, Huntington's disease and primary Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, brain trauma, epilepsy, brain tumors, etc.; 6. Patients with severe cardiac, pulmonary, or renal dysfunction (creatinine >2.0 mg / dl or 177 μmol / L), severe liver dysfunction (aminotransferase >3 times the normal value), or malignant tumors, and expected life expectancy <2 years; 7. Blood coagulation dysfunction or thrombocytopenia (platelets < 100 × 10 9 / L); 8. MRI scan not possible; 9. (1) Hereditary small vessel disease, (2) Inflammatory or immune-mediated small vessel disease, (3) Other cerebral small vessel disease, including venous collagen disease; 10. Pregnant, lactating or capable of becoming pregnant or planning to become pregnant; 11. Patients who have participated in other relevant clinical studies within the last 3 months or are currently participating in other relevant clinical studies; 12. Patients who are illiterate or have uncorrectable vision or hearing impairments and are unable to complete neuropsychological tests and scale evaluations.

[0050] Control group requirements: 1. Healthy individuals aged 60-80 years; 2. No autoimmune disease; 3. No vascular disease; 4. No infarct lesions; 5. Absence of sudden stroke-like episodes and no evidence of focal neurological damage early in the disease; 6. No history of long-term dizziness or posterior circulation ischemia.

[0051] 3. ELISA test Indirect ELISA detection was used in this experiment. 1. Day 1: The membrane was sealed with 100 μl / well of a coating solution (5 μg / ml of polypeptide) and coated overnight in a refrigerator at 4° C. 2. Day 2: (1) The plate was washed once with 200 μl / well of washing solution by leaving it to stand for 5 minutes. (2) The membrane was sealed with 100 μl / well of blocking solution and placed in an electrically heated constant temperature incubator for 2 hours. (3) After 2 hours, the plate was taken out, and samples and standards (100 μl / well) were added, sealed with a membrane, and placed in an electrically heated constant temperature incubator for 1 hour. (4) After 1 hour, the plate was removed and washed five times with 200 μl / well of washing solution. (5) The membrane was sealed with 50 μl / well of HRP-labeled goat anti-human antibody at room temperature for 30 minutes. (6) Step (4) was repeated. (7) The plate was incubated with 100 μl / well of coloring solution for 5-10 minutes, away from light. (8) The OD value was read at OD450nm in a microplate reader with 50 μl / well of stopping solution.

[0052] 4. Neuroglial cell experiments Day 1.1: 1 x 10 HMC3 cells 4 The plates were placed at 100 μl / well and allowed to adhere to the walls. 2. Day 2: Drugs were diluted and loaded with LPS (1 μg / ml), IL-4 (20 ng / ml), TNF (20 ng / ml), and TNF-related polypeptide (50 μM / ml) in the specified sequence. Three duplicate wells were prepared for each group, and the cells were co-cultured for 24 h. 3. Day 3: After 24 hours, the plate was removed and 10 μl / well of cck8 reagent was added. After further co-cultivation with the cells for 1 hour, the absorbance at OD450nm was detected.

[0053] 5. Mass spectrometry detection 1. Sample preparation: 1.1 Experimental materials: A. Patient serum B. Protein G-coupled filler 1.2 Experimental methods and procedures: A. Serum with high content of antibodies to Protein G-coupled TNF polypeptide itself: (1) 250 μl of protein G filler was taken, 500 μl of pure water was added, and the mixture was centrifuged at 1,000 rpm for 2 minutes, washed twice, and then washed once with PBS. (2) Take 30 μl of patient serum (diluted 1:25), and take 50 μl of the diluted serum to be used as a pre-adhesion sample for later concentration detection.

[0054] (3) The remaining diluted serum was incubated with protein G filler for 1 hour, and after incubation, 50 μl was taken and used as a post-adhesion sample, which was later used to detect the concentration. (4) The remainder was centrifuged at 1,500 rpm for 5 minutes, and the supernatant was discarded. (5) The protein G filler with antibodies in serum attached was used in the next attachment experiment.

[0055] B. Antibody-attached Protein G was incubated with serum samples with high TNF concentrations from a dementia patient group, eluted with 500 μl of 0.1 M glycine, pH 3.0, and the eluted material was subjected to mass spectrometry detection. Chemically synthesized P1516 (50 mg / ml) was diluted 50-fold with PBS to 1 mg / ml and used as a control in the above studies and subjected to mass spectrometry detection. 2. Mass spectrometry detection of molecular weight: An appropriate amount of the sample was taken, and 2 μL of PNGas F was added thereto. After incubation at 37° C. for 2 h, the complete molecular weight of the sample was detected by mass spectrometry.

[0056] 3. Analysis of the entire sequence of the sample: After concentrating the sample on a 10 kD vertical film, guanidinium chloride was added to a final concentration of 6 M, 1 M dithiothreitol was added to a final concentration of 20 mM, and the mixture was reacted at 56 ° C for 30 minutes. Furthermore, 1 M iodoacetamide was added to a final concentration of 50 mM, and the mixture was reacted in a dark room for 30 minutes. After that, the mixture was diluted to 6 times the initial volume with 25 mM ammonium bicarbonate solution, enzyme was added, and the enzyme was cleaved overnight at 37 ° C, after which the salt was removed with a C18 cartridge, and the mixture was redissolved by vacuum concentration and charged. Sequence alignment was performed using the data analysis software vanquish.

[0057] result: In this experiment, the detected specimens were sera from 14 Alzheimer's disease patients, 44 vascular dementia patients, 31 age-matched controls, and 100 healthy subjects. Basic information is shown in Table 1. [Table 2]

[0058] When TNF was coated and serum samples were detected, the concentration of the corresponding antibody in the serum of Alzheimer's disease patients was significantly higher than that of the control group of the same age group without cognitive impairment and the healthy control group of the health examination center (P<0.01, Figure 1). When P1516 polypeptide was coated and serum samples were detected, the concentration of the corresponding antibody in the serum of Alzheimer's disease patients was significantly higher than that of the control group of the same age group without cognitive impairment (P<0.001, Figure 2), and even more significantly higher than that of the healthy control group of the health examination center (P<0.0001, Figure 3). The concentration of the corresponding P1516 antibody in the serum of vascular dementia patients was very significantly higher than that of the control group of the same age group without cognitive impairment and the healthy control group of the health examination center (P<0.0001, Figures 4 and 5). In addition, P141516T, P1213, and P1920 polypeptides were all detected as antibodies that were significantly higher than the control group (Figures 7-11). On the other hand, other polypeptides derived from TNF, such as P141516, did not show significantly higher antibody levels than the control group (Figure 6). Thus, it can be seen that P1516, P141516T, P1213, and P1920 can all be used as coating polypeptides to detect or assist in the diagnosis of dementia.

[0059] For the 30 amino acid P1516, the inventors designed a series of short 10 or 20 amino acid polypeptides to cover different parts of the sequence of P1516, namely 10-1 to 10-21, 20-1 to 20-11. When the samples with high concentrations of P1516 antibodies were detected in serum, all of these polypeptides were able to effectively detect the corresponding antibodies in serum, but the detection results in serum samples from healthy subjects were all negative (Figure 12).

[0060] Comparing the detection of relevant autoantibodies in the serum of Alzheimer's disease (AD), vascular dementia (VD) and age-matched controls (Control) and healthy controls (Health) using the polypeptides of the present invention alone or in combination, it is found that the use of the combination provides greater sensitivity for detecting the relevant antibodies themselves (Figure 15).

[0061] The serum of a patient with high anti-TNF polypeptide antibodies was incubated with protein G, the antibodies were attached to protein G gel beads, and further incubated with serum of a patient with high TNF-α concentration to obtain co-immunoprecipitated products, which were dissociated from the protein G gel beads with glycine at pH 3.0, and the molecular weight of the co-precipitated products was detected by mass spectrometry, and the molecular weight of the main free small molecule in the product was found to be completely similar to that of the P1516 control polypeptide. The co-precipitated products were then enzymatically degraded with tryptase and peptide mapping was performed, which showed that the majority of the detected polypeptide sequences were concentrated in the P1213, P1516, and P1920 regions (Figure 13). This indicated that there were polypeptides in the serum of dementia patients that were equivalent in size to and similar in sequence to P1213, P1516, and P1920.

[0062] To clarify the effects of these polypeptides on the nervous system, human mycocyte HMC3 cells were used in the present invention. 4 HMC3 cells (1000 / well) were co-cultured with LPS (1μg / ml), IL-4 (20ng / ml), TNF (20ng / ml), and a series of TNF derivative polypeptides (50μM / ml, P78-P2122) for 24 hours, and then the CCK8 reagent was added to detect the cell viability. The results showed that compared with the control, the polypeptides P1516 and P1920 significantly reduced the number of viable HMC3 cells (Figure 14). These polypeptides were shown to have the effects of killing and inhibiting the growth of migroglia cells.

[0063] All documents related to the present invention are incorporated herein by reference as if each document were incorporated individually. After reading the above content of the present invention, it will be understood that those skilled in the art can make various changes and modifications to the present invention, and that equivalent forms thereof are within the scope of the claims of the present invention.

Claims

1. A TNF derivative polypeptide, (1) for use as a marker for diagnosing or detecting dementia, (2) for the manufacture of a reagent or kit for diagnosing or detecting dementia, or (3) for the manufacture of a drug for treating dementia.

2. 2. The use according to claim 1, wherein the TNF derivative polypeptide is one or more of the following: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26.

3. The use according to claim 1, characterized in that the dementia is Alzheimer's disease or vascular dementia.

4. A kit for diagnosing or detecting dementia, comprising a detection reagent and a container for containing the detection reagent, The detection reagent detects the presence or absence of a TNF derivative polypeptide or an antibody capable of binding to the TNF derivative polypeptide in the serum of a test subject, the TNF derivative polypeptide being: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26.

5. A TNF derivative polypeptide which is: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 4-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 4-26.

6. A combination of two or more TNF derivative polypeptides selected from the group consisting of: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26.

7. A binding agent or antagonist of a TNF derivative polypeptide, said TNF derivative polypeptide being: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26.

8. 1. Use of a binding agent or antagonist of a TNF derivative polypeptide for the manufacture of a medicament for treating dementia, wherein the TNF derivative polypeptide is: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26.

9. A pharmaceutical composition comprising a TNF derivative polypeptide binding agent or antagonist and optionally a pharma- ceutically acceptable excipient, said TNF derivative polypeptide being: 1) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26; or 2) A polypeptide having sequence similarity of at least 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 2-26.

10. 1. A method for detecting or diagnosing dementia, comprising the steps of: 1) detecting the presence or absence of a TNF derivative polypeptide or an antibody capable of binding to said TNF derivative polypeptide in the serum of a test subject, said TNF derivative polypeptide being a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs:2-26, or a polypeptide having 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence similarity to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs:2-26; 2) If the TNF derivative polypeptide or an antibody capable of binding to the derivative polypeptide is present in the serum of the subject, the subject is judged to have dementia.

11. 1. A method for prognosing dementia, comprising the steps of: 1) detecting the presence or absence of a TNF derivative polypeptide or an antibody capable of binding to said TNF derivative polypeptide in the serum of a test subject, said TNF derivative polypeptide being a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs:2-26, or a polypeptide having 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence similarity to a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs:2-26; 2) If the TNF derivative polypeptide or an antibody capable of binding to the derivative polypeptide is present in the serum of the subject, the prognosis of dementia in the subject is judged to be poor.